Receptor News and Research

RSS

New research questions reliability of macaque models for TIGIT-targeted cancer treatments

A new study published in the Journal of Biological Chemistry from UC Davis Comprehensive Cancer Center finds that TIGIT, an immune checkpoint receptor targeted by cancer immunotherapy drugs, triggers a different response in rhesus macaques compared to humans.

24 Nov 2025

Calcium-activated switch improves delivery and potency of cancer-fighting drugs

Cancer-fighting antibody drugs are designed to penetrate tumor cells and release a lethal payload deep within, but too often they don't make it that far.

24 Nov 2025

Study introduces cost-effective approach to analyze entire T-cell repertoire

Studying T cells, the immune cells most responsible for responding to infections and cancers, just received a significant boost in the form of a new technique from St. Jude Children's Research Hospital.

24 Nov 2025

GLP-1 discontinuation associated with more weight gain and pregnancy complications

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more weight and have higher risks of diabetes and hypertensive disorders during pregnancy, and experienced preterm delivery more so than people who had never taken GLP-1 drugs.

24 Nov 2025

Gut neurons control immunity attack or repair

Beneath the surface of your gut lies a vast network of neurons—as many as in your spinal cord. New research from the Champalimaud Foundation (CF) in Lisbon shows that in mice this "second brain" helps decide whether the immune system should go into attack mode or start repairing tissue.

24 Nov 2025

Dexamethasone shows potential to fight therapy-resistant breast cancer metastases

The drug dexamethasone supplements cancer treatments to alleviate side effects of chemotherapy such as nausea or inflammation.

24 Nov 2025

Study finds GLP-1 drugs improve strength and reverse aging biology in mice

Researchers showed that GLP-1 receptor agonism counteracts aging across multiple organs in mice, improving strength and reversing molecular aging signatures without meaningful effects on body weight. These benefits depended largely on hypothalamic GLP-1R signaling and closely mirrored the anti-aging patterns produced by rapamycin.

23 Nov 2025

Does coffee truly boost memory and focus or is it all hype?

Coffee’s bioactive compounds, especially caffeine, show potential cognitive, neuroprotective, and neuroplasticity benefits across animal and human studies. However, most findings are observational, mechanisms remain uncertain, and optimal intake is still unclear.

23 Nov 2025

New signaling molecule drives development of tissue resident memory T cells

We owe a lot to tissue resident memory T cells (TRM). These specialized immune cells are among the body's first responders to disease.

22 Nov 2025

Comprehensive antibody map reveals how SARS-CoV-2 mutations evade immunity

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have created the most comprehensive map to date showing how antibodies attach to the SARS-CoV-2 virus, which causes COVID-19, and how viral mutations weaken that attachment.

21 Nov 2025

CAR T cell therapy could be a highly effective tool against atherosclerosis

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition where a build-up of plaque in the arteries reduces blood flow, leading to heart attacks and strokes.

21 Nov 2025

New neuron signaling mechanism reveals safer pathway for pain treatment

Researchers at Tulane University, with a team of colleagues from eight other universities, have discovered a new nerve cell signaling mechanism that could transform our understanding of pain and lead to safer, more effective treatments.

20 Nov 2025

Inflammatory biomarkers offer new insights for precision medicine in ischemic stroke

Ischemic stroke, a leading cause of disability and mortality worldwide, is a complex cerebrovascular event with outcomes heavily influenced by the inflammatory response.

20 Nov 2025

Oral GLP-1 pill shows strong weight loss and blood sugar benefits in adults with diabetes

A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher.

20 Nov 2025

Searches for “Ozempic face” surge as people look for filler-based solutions

Public interest in “Ozempic face” rose sharply from 2022 to 2025, mirrored by increased searches for nonsurgical facial filler procedures. Surgical terms showed neutral or negative associations, indicating consumers are primarily exploring filler-based solutions for GLP-1RA-related facial volume loss.

20 Nov 2025

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

Engineered CAR-T cells show promise against glioblastoma in preclinical models

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.

20 Nov 2025

Fruit fly study reveals brain mechanism underlying motivation fatigue

Our brain's reward system processes and reinforces pleasurable experiences, motivating us to seek out and engage in rewarding activities ranging from eating to social interactions to recreational drug use.

20 Nov 2025

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects.

20 Nov 2025